INAB
IN8BIO, INC.
Next earnings Aug 5, 2026 · consensus $-0.38 EPS
Last earnings +1.3% on 2026-05-07
$1.36
▲ 0.00%$1.36▼ -36.15%
over 1Y
L $1.21EODHDH $2.59
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.0%
1W-0.0%
1M-24.4%
3M-3.5%
YTD-44.7%
1Y-36.2%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 10 analysts
Buy
Conservative balance sheet (liabilities/equity 0.17x).
Return on equity -70.5% · latest
IN8BIO, INC. shows limited reported revenue, and -70.5% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$14.7M | -$28.5M | -$30.0M | -$30.4M | -$19.4M |
| Net income | -$14.7M | -$28.5M | -$30.0M | -$30.4M | -$19.4M |
| Diluted EPS | -$1.47 | -$1.36 | -$1.00 | -$17.05 | -$4.44 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$31.6M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-33.0%
FCF yield—
Quality & risk
ROIC (est.)-55.7%
Free cash flow—
Total debt—
Net cash$27.3M
Piotroski F-Score3/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+73.6%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — agreement terminated (2026-06-01). Worth a closer look.
- 8-K Agreement terminated2026-06-01
- S-3/A Shelf registration (potential raise)2026-05-18
- 8-K Officer / director change2026-05-07
- 10-Q Quarterly report2026-05-07
- DEF 14A Proxy statement2026-03-26
- 8-K Earnings results2026-03-12
- 10-K Annual report2026-03-12
- 8-K Officer / director change2026-02-27
- 8-K Officer / director change2026-02-09
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-05-292026-06-01open ↗424B5Filing2026-06-01open ↗SCHEDULE 13D/AFiling2026-05-29open ↗4Period ending 2026-05-272026-05-29open ↗EFFECTFiling2026-05-19open ↗S-3/AFiling2026-05-18open ↗4Period ending 2026-05-092026-05-12open ↗4Period ending 2026-05-092026-05-12open ↗4Period ending 2026-05-092026-05-12open ↗4Period ending 2026-05-092026-05-12open ↗4Period ending 2026-05-092026-05-12open ↗4Period ending 2026-05-092026-05-12open ↗
Frequently asked
- Is IN8BIO, INC. (INAB) a buy?
- INAB currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.17x).
- What is IN8BIO, INC.'s quality score?
- INAB scores 59.87179487179487/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001740279, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 8:08:26 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.